KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

AbbVie (ABBV) Long-Term Debt Repayments (2016 - 2025)

AbbVie has reported Long-Term Debt Repayments over the past 11 years, most recently at $8.0 million for Q4 2025.

  • Quarterly Long-Term Debt Repayments fell 99.86% to $8.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.8 billion through Dec 2025, down 29.29% year-over-year, with the annual reading at $6.8 billion for FY2025, 29.29% down from the prior year.
  • Long-Term Debt Repayments was $8.0 million for Q4 2025 at AbbVie, down from $9.0 million in the prior quarter.
  • Over five years, Long-Term Debt Repayments peaked at $6.9 billion in Q4 2022 and troughed at $2.0 million in Q2 2022.
  • The 5-year median for Long-Term Debt Repayments is $2.2 billion (2021), against an average of $2.3 billion.
  • Year-over-year, Long-Term Debt Repayments crashed 99.94% in 2022 and then soared 50000.0% in 2023.
  • A 5-year view of Long-Term Debt Repayments shows it stood at $3.8 billion in 2021, then skyrocketed by 82.6% to $6.9 billion in 2022, then tumbled by 73.81% to $1.8 billion in 2023, then skyrocketed by 221.18% to $5.8 billion in 2024, then tumbled by 99.86% to $8.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Long-Term Debt Repayments are $8.0 million (Q4 2025), $9.0 million (Q3 2025), and $3.8 billion (Q2 2025).